Document is current
Any future updates will be listed below
-
Authors
Yang, Fan https://orcid.org/0000-0003-3106-7593
He, Zhenqiang
Duan, Hao
Zhang, Duo https://orcid.org/0000-0003-3215-2466
Li, Juehui
Yang, Huijuan
Dorsey, Jay F.
Zou, Wei
Nabavizadeh, S. Ali
Bagley, Stephen J.
Abdullah, Kalil
Brem, Steven
Zhang, Lin https://orcid.org/0000-0003-1998-0611
Xu, Xiaowei
Byrne, Katelyn T.
Vonderheide, Robert H.
Gong, Yanqing
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS106108)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01CA241501)
- License Information
-
More Information
Article History
Received: 9 September 2020
Accepted: 17 May 2021
First Online: 8 June 2021
Change Date: 23 August 2021
Change Type: Update
Change Details: In the original version of this Article, the given and family names of author S. Ali Nabavizadeh were incorrectly tagged, leading to incorrect indexing. This error has now been corrected. The PDF and HTML versions displayed the name correctly at the time of publication.
Competing interests
: S.J.B. is an advisor to Bayer, Novocure, and Sumitomo Dainippon. S.J.B. has received research funding support from Incyte, GSK, Novocure, and Eli Lilly. L.Z. reports having received research funding from AstraZeneca, Bristol-Myers Squibb/Celgene, and Prelude Therapeutics. X.X. owns stocks in CureBiotech and Exio Bioscience. R.H.V. reports being an inventor on a licensed patent application for cellular immunotherapy. R.H.V. reports receiving royalties for the license of a research grade monoclonal antibody. Y.F. is a co-founder of Radix Therapeutics. The other authors have no competing interests.
